Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Oooooh, That’s Scary! Welcome to the Dark Side of Biopharma

For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

Read More »

Study shows more thinking problems in former pro soccer players

A study of more than a thousand former professional soccer players has uncovered significantly more deaths from brain disease than among non-players.

Read More »

Biogen R&D Head Departs for New Role

After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.

Read More »

Biogen Halts Mid-Stage IPF Drug Trial

Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.

Read More »

New Gene-Editing Tool, SATI, Focuses on Non-Coding Regions of the Genome

Researchers with the Salk Institute developed a new type of gene editing called SATI that may provide the option of editing numerous gene mutation diseases such as Huntington’s disease and the rare premature aging syndrome, progeria.

Read More »

Arizona State University Researchers Try Novel Approach to Alzheimer’s Prevention

Researchers at Arizona State University are experimenting with a compound that might prevent Alzheimer’s and other neurodegenerative diseases, such as Parkinson’s disease, and potentially Down syndrome.

Read More »

Rutgers’ Nanotechnology Research Might Help with Alzheimer’s, Parkinson’s and Other Diseases

Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.

Read More »

RegenxBio and Pfizer Partner on Gene Therapy

Rockville, Maryland-based RegenxBio entered a license deal with Pfizer for a gene therapy for Friedreich’s ataxia, the most common hereditary ataxia.

Read More »

InvaGen Receives FDA Approval for Generic of Pfizer’s Lyrica

The U.S. FDA approved InvaGen Pharmaceuticals’ generic version of Pfizer’s Lyrica (pregabalin) for eight different dosages.

Read More »

Genentech Strikes Three Drug Discovery Deals

In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom